AFP and hepatocellular carcinoma: A proof-of-concept study done as part of the TENDENCY study at University Hospital Coventry & Warwickshire (UHCW) with 141 participants (including 39 HCC cases) showed mSEPT9 to have a sensitivity of 89% and a specificity of 81% (in comparison to an AFP sensitivity of 50% and a specificity of 97%) [14].